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Abstract
Background: When the steroid hormones estrogen and progesterone bind to nuclear receptors,
they have transcriptional impact on target genes in the human endometrium. These transcriptional
changes have a critical function in preparing the endometrium for embryo implantation.
Methods: 382 genes were selected, differentially expressed in the receptive endometrium, to
study their responsiveness of estrogen and progesterone. The endometrial cell lines HEC1A and
RL95-2 were used as experimental models for the non-receptive and receptive endometrium,
respectively. Putative targets for activated steroid hormone receptors were investigated by
chromatin immunoprecipitation (ChIP) using receptor-specific antibodies. Promoter occupancy of
the selected genes by steroid receptors was detected in ChIP-purified DNA by quantitative PCR
(qPCR). Expression analysis by reverse transcriptase (RT)-PCR was used to further investigate
hormone dependent mRNA expression regulation of a subset of genes.
Results: ChIP-qPCR analysis demonstrated that each steroid hormone receptor had distinct group
of target genes in the endometrial cell lines. After estradiol treatment, expression of estrogen
receptor target genes predominated in HEC1A cells (n = 137) compared to RL95-2 cells (n = 35).
In contrast, expression of progesterone receptor target genes was higher in RL95-2 cells (n = 83)
than in HEC1A cells (n = 7) after progesterone treatment. RT-PCR analysis of 20 genes
demonstrated transcriptional changes after estradiol or progesterone treatment of the cell lines.
Conclusions: Combined results from ChIP-qPCR and RT-PCR analysis showed different patterns
of steroid hormone receptor occupancy at target genes, corresponding to activation or
suppression of gene expression after hormone treatment of HEC1A and RL95-2 cell lines.
Background
The human endometrium is a dynamic tissue that under-
goes cyclic changes in preparation for endometrial recep-
tivity and embryo implantation. Endometrial
development consists of proliferative and secretory
phases, and the two major regulators of this process are
the ovarian steroid hormones 17β-estradiol (E2) and pro-
gesterone (P4). In the proliferative phase, estrogens stim-
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ulate the proliferation of the epithelial and stromal
components of the endometrium, while in the secretory
phase P4 is involved in glandular differentiation and inhi-
bition of E2-mediated cell proliferation [1]. In the absence
of implantation, declining levels of P4 and E2 signal the
degeneration of the endometrial tissue, which is followed
by regeneration during the next cycle.
The biological activities of E2 and P4 are mediated mainly
by nuclear receptors (NRs). Binding of a steroid hormone
to its cognate receptor results in a conformational change
in the NR that allows the ligand-NR complex to bind with
high affinity to response elements in DNA and regulate
transcription of target genes. Two types of E2 receptors,
ERα and ERβ, encoded by separate genes, are found in
humans [2,3]. Although ERα and ERβ are present in all
endometrial cell types over the entire menstrual cycle,
they are expressed at higher levels during the proliferative
phase and show lower activity during the secretory phase
because of the suppressive effect of P4 [4].
P4 signalling is also mediated by two receptors, PRA and
PRB [5], which are encoded by the same gene but tran-
scribed from different promoters, resulting in a PRB that
has an additional 164 amino acids at the N-terminus [6].
PRB is a stronger transcriptional activator in most cell
types, while PRA acts often as a dominant negative repres-
sor for PRB activity [7,8]. PRA and PRB levels are similar
during the proliferative phase. In the early secretory
phase, PRA is dominant, while higher PRB levels during
the mid-secretory phase have been described [9]. The
expression of the PR gene in endometrial glands is con-
trolled by E2 and P4, where E2 induces PR synthesis and
P4 down-regulates the expression of its own receptor [1].
Implantation of the developing embryo involves a molec-
ular dialogue between the endometrium and blastocyst
that involves a number of specific mediators including
membrane receptors, components of the extra-cellular
matrix, growth factors, cytokines and lipid components of
the cell membranes [10]. The endometrium is receptive
for embryo attachment only during a restricted period
called the "implantation window" (IW). In humans, the
IW is limited to days 20-24 of the menstrual cycle and is
achieved through the coordinated action of P4 and E2.
Thus, an imbalance of steroid hormone levels and their
ratios could influence the regulation of target genes, lead-
ing to female infertility by disturbing endometrial recep-
tivity during the IW.
Microarray technology has led to genome-wide identifica-
tion of gene expression pathways involved in implanta-
tion events. Based on five transcriptome studies [11-15],
we selected 382 genes with different expression levels dur-
ing the IW in human endometrium. The aim of this study
was to investigate whether these pre-selected genes could
be directly regulated by E2 and P4 through their specific
receptors. To achieve the purpose, to study hormone
dependent receptivity of the endometrium, we used two
human uterine epithelial cell lines as in vitro models.
HEC1A was used as a model of non-receptive
endometrium, and RL95-2 was used as a model of recep-
tive endometrium [16-19]. The cell lines were chosen
based on earlier studies which have demonstrated that
RL95-2 cells have stronger adhesiveness for human JAR
choriocarcinoma multicellular spheroids compared to
HEC1A cells [20-22] and are thus considered as a model
of the receptive endometrium. Following hormone treat-
ment of the cells, binding of steroid hormone receptors to
the promoters of selected genes was investigated by chro-
matin immunoprecipitation (ChIP) with specific anti-
bodies, and detection of the isolated genomic sequences
with quantitative PCR (qPCR). E2- and P4-dependent




HEC1A (#HTB-112, American Type Culture Collection,
ATCC, Teddington, UK) cells were grown in McCoy 5A
medium (#A1324, AppliChem GmbH, Darmstadt, Ger-
many), while RL95-2 (#CRL-1671, ATCC) cells were
maintained in DMEM/F12 (AppliChem GmbH) medium
with 10 mM Hepes and 5 μl/ml insulin. Both media were
supplemented with 2 g/L sodium bicarbonate (Appli-
Chem GmbH), 10% fetal bovine serum (FBS) (Appli-
Chem GmbH) and 1% penicillin/streptomycin
(AppliChem GmbH). Both studied cell lines express E2
and P4 specific nuclear receptors (ERα, ERβ, PRA, PRB) as
indicated by the ATCC. For hormonal treatment, E2
(Sigma-Aldrich, Helsinki, Finland) or P4 (4-Pregnene-
3,20-dione, Sigma-Aldrich) was added to the culture
media to a final concentration of 10-8M as described
before [23,24]. For cultures with hormone supplements,
dextran-coated charcoal-treated FBS and media without
phenol red were used for 48 h prior to experiments to
adapt similar conditions and avoid possible hormone-
like (estrogenic) activity of Phenol red. Hormone treat-
ment was 45 min for ChIP experiments and 3 h, 6 h or 12
h for mRNA experiments.
Chromatin immunoprecipitation
Chromatin was immunoprecipitated as previously
described [25], using following antibodies: monoclonal
mouse anti-human ERα antibody (D-12, sc-8005); poly-
clonal rabbit anti-human ERβ antibody (H-150, sc-8974);
monoclonal mouse anti-human PRAB antibody (AB-52,
sc-810) that recognizes both human PRA and PRB recep-
tors (AB-52, sc-810); and monoclonal mouse anti-humanReproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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PRB antibody (B-30, sc-811) that recognizes only the
additional NH2-terminal stretch of PRB receptor (Santa
Cruz Biotech, CA, USA). Preliminary experiments deter-
mined an optimal formaldehyde cross-linking time of 15
min for both cell lines. Chromatin was fragmented to an
average size of 0.5 - 2 kb using a Vibra-Cell ultrasonic
processor (Sonics, Newtown, CT USA). Antibody-antigen
complexes were precipitated with GammaBind™ plus
Sepharose™ (GE Healthcare Life Sciences, Uppsala, Swe-
den), eluted with hot 0.1% SDS and uncrosslinked over-
night at 65°C in the presence of Protein K (Sigma-
Aldrich). DNA was purified using a Gel Extraction Kit
(Qiagen, Helsinki, Finland). Control experiments used
preimmune total IgG (Cell Signalling Technology, Inc,
Danvers, MA, USA) to estimate the non-specific binding
by unspecific antibodies.
ChIP-qPCR for detection of genomic sequences
Specific genomic regions in the ChIP DNA samples were
detected by qPCR. The 382 genomic targets for PCR were
selected from previously published endometrial tissue
microarray data (See additional file 1) [11-15] using two
criteria: (i) ≥ 2-fold up- or down-regulated mRNA expres-
sion during IW and (ii) evolutionary conservation of
human and murine orthologous sequences. Primers were
designed to detect and amplify a region from +1000 to -
5000 bp from the transcription start site using the Primer3
program [26] detecting NR involvement in formation of
the basal transcription complex. All primers were
designed to have a melting temperature (Tm) of 60°C.
Primer specificity was controlled using the alignment
algorithms BLAT/iPCR [27] and BLAST [28] to search the
whole human genome. Primers were obtained from
MWG Biotech (Edsberg, Germany). PCR was performed
using HotStarTaq Master Mix (Qiagen) with 0.05 ng of
template DNA and 1.25 pmol of primers for each reac-
tion, according to the manufacturer's instructions.
PCR products were detected by qPCR using 384-well
plates and a SYBR green detection method with an ABI
HT7900 RT-PCR machine (Applied Biosystems, Foster
City, CA, USA). PCR conditions were: HotStarTaq DNA
Polymerase activation step for 14.5 min at 95°C, 40 cycles
of denaturation for 30 s at 95°C, annealing for 45 s at
58°C and extension for 45 s at 72°C. A dissociation step
was added to confirm the purity of PCR products by melt-
ing-curve analysis with 5 min ramping from 60°C to
95°C.
RT-PCR
RNA was extracted using an RNeasy Mini Kit (Qiagen).
Cells were washed once with phosphate-buffered saline
prior to extraction, lysed directly in the tissue culture dish
and homogenized by 10 strokes with an insulin syringe.
RNA was prepared according to the manufacturer's proto-
col. Genes (n = 20, ADAMDEC1,  CD86,  ETV1,  FLT1,
FOXA2,  GRIP1,  HES1,  HOXA1,  IHH,  KLK3,  MEF2D,
MMP7,  NCOA1,  OTOF,  PLXNA2,  RELB,  SMARCA2,
TBX19, TNC, and ZNF54) were chosen for RT-PCR analy-
sis based on positive ChIP experiment results, focusing
mostly on transcription factors (See additional file 2). For
mRNA analysis, 5 μg of total RNA was subjected to reverse
transcription, using SuperScript® III First-Strand Synthesis
SuperMix (#18080-400, Invitrogen Life Technologies,
Carlsbad, CA, USA), as described by the manufacturer.
GAPDH  specific primers were used to normalize the
cDNA synthesis with forward and reverse primers
CTCTCTGCTCCTCCTGTTCGAC and TGAGCGATGT-
GGCTCGGCT, respectively. cDNA specific primer pairs
were designed using Primer3 software and tested for
unspecific priming against human genomic and mRNA
sequences using iPCR software (MWG Biotech). Primers
were designed to generate amplicons of 75-150 bp with a
Tm of 60°C. PCR conditions for reverse transcriptase
products were as described above with the exception of a
15 s annealing step at 58°C, and a 30 s extension time to
account for the shorter PCR products.
RT-PCR data analysis
Quantitative qPCR results were analysed using the pub-
licly available software Miner [29]. Outliers were excluded
manually when the mean coefficient of variation (CV) for
CT (cycle threshold) for triplicates was >1%. Expression
values for all transcripts were normalized to the endog-
enous control of GAPDH, and ratios relative to non-
treated samples were generated. Relative gene expression
ratios were calculated according to GED (Gene Expression
Difference) by CT protocol [30], using the average effi-
ciency of each gene and the CT of each triplicate. To com-
pare the effects of hormone treatments on HEC1A and
RL95-2 cell lines, statistical analysis was performed on
log2-transformed values of gene expression ratios using
an unpaired Student's t-test at a 95% confidence level.
Annotation of genes
Gene classifications were carried out using the PANTHER
(Protein Analysis THrough Evolutionary Relationships),
[31] classification system that specifies genes by functions
based on published evidence and evolutionary relation-
ships that predict gene function in the absence of direct
experimental evidence. Clustering analysis was performed
with the Cluster 3.0 program [32], using uncentered cor-
relation and complete centroid linkage. Inverted CT
(CTinv) values were used for clustering qPCR data. The
baseline was set to 40 and CTinv was calculated as CTinv
= 40-Ct. Visualisation of clustering data was done using
Java TreeView software.
Gene annotation, sequence information, gene descrip-
tions and accession numbers (IDs) were downloadedReproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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from BioMart [33] NCBI [34] and UCSC genome browser
[35] databases. All datasets were imported and kept in a
database supported by MySQL database management
software [36].
Results
E2- and P4-receptor target genes in HEC1A and RL95-2 
cells
Two endometrial cell lines, HEC1A and RL95-2, were used
to investigate the steroid hormone-dependent binding of
NRs to the promoters of 382 IW-specific genes (See addi-
tional file 1). Although the native receptive endometrium
is under the combined influence of both E2 and P4, we
performed hormonal treatments separately to reveal E2 or
P4 dependent action through their specific nuclear recep-
tors. Cells were treated with either E2 or P4 followed by
ChIP using antibodies against the steroid hormone recep-
tors: ERα, ERβ, PRB, or PRAB (which recognizes both PRA
and PRB receptors). Quantitative qPCR with specific
primers was used to detect NR-binding to the promoter
region of the selected genes. HEC1A cells were treated
with E2 to simulate the non-receptive-like endometrium
and with P4 for comparing P4 effects on the two endome-
trial cell lines. Out of 382 investigated genes, 137 were ER
targets: 101 were bound by ERα, 96 were bound by ERβ,
and 60 were targets of both receptors (Figure 1A). When
the targets common to both ERs (n = 56) and the targets
shared by ERs and PRs (n = 7) were excluded, 40 genes
were found to be exclusively regulated by ERα and 34
genes by ERβ (Table 1).
The amino acid sequence of the progesterone receptor
PRA is contained within the sequence of PRB, so produc-
ing antibodies specific to PRA is not feasible. Therefore,
PRA target genes were found by subtracting anti-PRB tar-
gets from the common pool of all PRAB-targets as PRB
and PRAB overlapping target genes were considered to be
PRB-specific. Seven target genes for P4-mediated action in
HEC1A cells were identified, 5 for PRA and 2 for PRB (Fig-
ure 1A). All PR targets overlapped with ER targets and thus
they were not considered to be unique targets for P4
action in HEC1A cells (Table 2).
The RL95-2 cell line was used as a model for the receptive
endometrium with E2 and P4 treatments performed sepa-
rately. ChIP-qPCR analysis revealed four distinct groups
of target genes for each steroid hormone receptor (ERα,
ERβ, PRA, and PRB) in RL95-2 cells (Figure 1B). After P4
treatment, anti-PR antibodies recognized chromatin from
83 out of the 382 potential target genes; anti PRB for 40
and anti-PRAB for 52, including overlapping targets for
two antibodies. After removing common targets between
PRs and ERs and subtracting anti-PRB targets from the
common pool of all PRAB-targets, 37 genes were consid-
ered to be unique targets for PRA and 8 for PRB (Table 3).
Although PRAB antibody should detect both PRA and
PRB receptor subtypes, 31 genes were targeted solely by
PRB and not identified by PRAB antibody. Twenty-five of
them were found to be PRB specific, while six were addi-
tionally co-regulated by at least one of the ERs. These 25
unique PRB targets were also regarded as PRB-specific,
thus resulting in 33 unique PRB target genes (Table 3). E2
treatment of RL95-2 cells resulted in 35 genes bound by
ERs, where in total 17 loci were immunoprecipitated by
ERα and 24 by ERβ antibody (Figure 1B), including over-
lapping targets for two antibodies. After deducted com-
mon targets, we discovered nine unique target genes for
ERα, eight for ERβ (Table 4), and five common targets for
both ERs (data not shown).
The total number of genes targeted after E2 treatment of
HEC1A and RL95-2 cells is shown in Figure 1. Approxi-
mately four times as many genes were bound by ERs in
HEC1A cells than in RL95-2 cells, which had 137 and 35
target genes, respectively. These results confirmed that
HEC1A is a better model of the non-receptive
endometrium with E2 exerting its primary role in tissue
proliferation. In contrast, P4 treatment resulted in 10
times more PR targets in RL95-2 cells (n = 83) than in
HEC1A cells (n = 7), supporting the view of RL95-2 cell
line as a model for the receptive endometrium with P4
preparing the endometrium for embryo nidation.
E2- and P4-mediated mRNA expression in HEC1A and 
RL95-2 cell lines
To elucidate the biological significance of the molecular
interactions seen by ChIP, we complemented the initial
results with mRNA expression studies for 20 genes (See
additional file 2). All selected genes were detected as NR
targets by ChIP-qPCR and half (n = 10) of them were clas-
sified as transcription factors. The other criteria after tran-
scription factors was to find genes which has not been
described as an ER or PR targets before.
HEC1A and RL95-2 cells were treated with E2 or P4 for 3,
6, or 12 h. At least 2-fold up- or down-regulation of
mRNA expression levels were detected for 12 genes
(CD86,  FOXA2,  IHH,  MEF2D,  MMP7,  NCOA1,  OTOF,
PLXNA2, RELB, SMARCA2, TNC, and ZNF549) out of 20
genes studied (Table 5). Although, the activities of tran-
scription factor coding genes GRIP1 and TBX19 changed
significantly during the hormonal treatments, these alter-
ations remained below the 2-fold threshold. cDNA ampli-
fication was not observed for 6 genes ADAMDEC1, ETV1,
FLT1, HES1, HOXA1 and KLK3 in either cell line regard-
less of hormonal treatment (data not shown). Surpris-
ingly, the observed changes in E2- or P4-dependent
mRNA expression occasionally conflicted with the ChIP-
qPCR results. For example, although the secreted growth
factor Indian hedgehog (IHH) and otoferlin (OTOF) wereReproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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detected as E2-ER targets in HEC1A cells, E2-induced
mRNA expression was observed in RL95-2 cells but not in
HEC1A cells.
From the selected 20 genes five genes showed significant
cell line-specific mRNA expression either in HEC1A or
RL95-2 cell line (Table 5, in bold). IHH expression was
detected in RL95-2 cell line-specific manner until 6 h after
E2 treatment or 3 h after P4 treatment, but was down-reg-
ulated after longer hormonal exposure. In addition to
IHH, the expression of three other genes: plexin A2
(PLXNA2), OTOF and a SWI/SNF related family member
(SMARCA2) were induced by E2 or P4 in the RL95-2 cell
line. In HEC1A cells, on the contrary, the expression of
matrix metalloprotease 7 (MMP7) was detected in non-
treated HEC1A cells and was gradually down-regulated
after treatments by both hormones.
Table 1: List of unique target genes for ERα and ERβ in HEC1A cell line after E2 treatment
Gene symbol* Gene name
Unique targets for ERα Unique targets for ERβ
ABCB10 ATP-binding cassette, subfamily B, member 10 AQP3 Aquaporin 3
ADCYAP1 Adenylate cyclase-activating polypeptide 1 B3GAT3 Beta-1,3-glucuronyltransferase 3
AGL Amylo-1,6-glucosidase, 4-alpha- glucanotransferase BMP10 Bone morphogenetic protein 10
APRT Adenine phosphoribosyltransferase CLU Clusterin
ARID5B AT-rich interaction domain-containing protein 5B COG5 Component of oligomeric golgi complex 5
C3orf1 Chromosome 3 open reading frame 1 CRSP9 Mediator complex subunit 7
CCL11 Chemokine, CC motif, ligand 11 DMBT1 Deleted in malignant brain tumors 1
CCL7 Chemokine, CC motif, ligand 7 DNAH9 Dynein, axonemal, heavy chain 9
CCT6B Chaperonin-containing T-complex polypeptide 1, 
subunit 6B
FECH Protoporphyria, erythropoietic
CD86 Cd86 antigen FEN1 FLAP structure-specific endonuclease 1
CEACAM3 Carcinoembryonic antigen-related cell adhesion 
molecule 3
FYB FYN-binding protein
CLDN4 Claudin 4 GBAS Glioblastoma amplified sequence
ECM1 Extracellular matrix protein 1 GPX3 Glutathione peroxidase 3
EDN3 Endothelin 3 GRIP1 Glutamate receptor-interacting protein 1
FBLN2 Fibulin 2 HBB Hemoglobin--beta locus
FOSL1 FOS-like antigen 1 KIAA0427 KIAA0427
GRIK1 Glutamate receptor, ionotropic, kainate 1 LGTN Ligatin
GSN Gelsolin MEF2D Myocyte enhancer factor 2D
HOXA1 Homeobox A1 NINJ1 Nerve injury-induced protein 1
ITGB7 Integrin, beta-7 PDGFA Platelet-derived growth factor, alpha polypeptide
ITPA Inosine triphosphatase PENK Proenkephalin
LGALS8 Lectin, galactoside-binding, soluble, 8 PLXNB3 Plexin B3
MB Myoglobin PRODH Proline dehydrogenase
NEK6 Never in mitosis gene a-related kinase 6 SC65 Synaptonemal complex protein SC65
NID2 Nidogen 2 SERPIND1 Heparin cofactor II
ODF2 Outer dense fiber of sperm tails 2 SLC16A4 Solute carrier family 16 (monocarboxylic acid transporter), 
member 4
POFUT1 Protein o-fucosyltransferase 1 TDG Thymine-DNA glycosylase
PWP1 PWP1 homolog (S. Cerevisiae) TFDP1 Transcription factor DP1
RELB v-rel avian reticuloendotheliosis viral oncogene 
homolog b
TGM2 Transglutaminase 2
SEC61B SEC61 complex, beta subunit TNC Tenascin C
SFRS16 Splicing factor, arginine/serine- rich 16 TNFRSF10C Tumor necrosis factor receptor superfamily, member 10c
SGCB Sarcoglycan, beta TP63 Tumor protein p63
SPARC Secreted protein, acidic, cysteine-rich TRIP10 Thyroid hormone receptor interactor 10
SPATA2 Spermatogenesis-associated protein 2 WFDC2 WAP four-disulfide core domain 2
SSFA2 Sperm-specific antigen 2
TFAP2C Transcription factor AP2-gamma
TRH Thyrotropin-releasing hormone deficiency
TRIM16 Tripartite motif-containing protein 16
WNT5A Wingless-type MMTV integration
site family,
member 5A
XCL2 Chemokine, C motif, ligand 2
(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).Reproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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Analysis of gene expression in HEC1A and RL95-2 cell
lines showed almost opposite responses to E2 and P4. A
significant difference (p < 0.05) in transcript levels was
observed between the two cell lines in the expression of
nine genes after E2 treatment (Figure 2). Furthermore,
CD86, FOXA2, GRIP1, NCOA1, RELB, TBX19, TNC, and
ZNF549 genes showed opposite regulation in the two cell
lines, with mRNA levels up-regulated in RL95-2 cells but
down-regulated in HEC1A cells after E2 treatment when
compared to non-treated samples (Figure 2). The expres-
sion of MEF2D was also significantly different between
the cell lines, but unlike the other genes, it was up-regu-
lated by E2 in both cell lines. P4 similarly exerted opposite
effects on gene expression in the two endometrial cell
lines as mRNA levels of the three transcription factor
genes FOXA2, NCOA1, TBX19, and extracellular matrix
tenascin-C (TNC) gene were significantly (p < 0.05, Figure
3) up-regulated in RL95-2 cells and down-regulated in
HEC1A cells post P4 treatment.
Discussion
The exact molecular characteristics of the embryo impan-
tation are still not completely characterised because of the
complexity of using human embryos and endometrial tis-
sue in reseach, therefore other means must be elucidated
for research of receptivity of the endometrium. Used
RL95-2 and HEC1A cell lines are both described as
endometrial epithelial cell lines derived from adenocarci-
noma cells. Our interest to investigate the suitability of
Cluster analysis of ERα, ERβ, PRAB, PRB target genes in HEC1A and RL95-2 cells after E2 or P4 treatment Figure 1
Cluster analysis of ERα, ERβ, PRAB, PRB target genes in HEC1A and RL95-2 cells after E2 or P4 treatment. 
Target genes revealed from ChIP-qPCR experiment were clustered with Cluster 3.0 program and visualized using Java 
TreeView software. A. HEC1A cell line. E2+ERα: 101 ERα target genes after E2 treatment; E2+ERβ: 96 ERβ target genes after 
E2 treatment; P4+PRAB: 7 PRAB target genes after P4 treatment; and P4+PRB: 2 PRB target genes after P4 treatment. B. RL95-
2 cell line. E2+ERα: 17 ERα target genes after E2 treatment; E2+ERβ: 24. ERβ target genes after E2 treatment; P4+PRAB: 52 
PRAB target genes after P4 treatment; and P4+PRB: 40 PRB target genes after P4 treatment.
Table 2: List of PRA and PRB target genes in HEC1A cell line 
after P4 treatment
Gene symbol* Gene name
Targets for PRA
CD28 CD28 molecule
COL5A2 Collagen, type V, alpha-2
ETS2 V-Ets avian erythroblastosis virus
e26 oncogene homolog 2
MYST4 Histone acetyltransferase MYST4
OTOF Otoferlin
Targets for PRB
TCF4 Transcription factor 4
ZNF167 Zinc finger protein 167
(*) Official gene symbol by HUGO Gene Nomenclature Committee 
(HGNC).Reproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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selected cell lines as an in vitro models of non-receptive
and receptive endometrium was based on several studies
published recently [21,22,37,38]. RL95-2 cell line has
been characterized as a model of receptive endometrium
by its ability to mimic relevant properties of the adhesion
competent endometrial lining compared to HEC1A
[21,22].
The steroid hormones E2 and P4 bind to NRs to play a key
role in preparing the endometrium for implantation of an
embryo. NRs regulate transcription by binding to the
proximal or distal regulatory regions of specific genes.
Transcriptional changes regulated by NRs have been sug-
gested to involve chromosomal looping or PolII tracking
that allows enhancers to interact with the transcription
complex at the promoter [39]. In this study, we used
ChIP-qPCR method to investigate whether genes previ-
ously identified as IW-specific become direct targets of
NRs after hormonal treatment of endometrial cells.
Combining new technologies based on microarrays and
high-throughput sequencing with the today's knowledge
of entire human genome allows defining of all in vivo tar-
gets for transcription machinery in a single experiment
Table 3: List of unique target genes for PRA and PRB in RL95-2 cell line after P4 treatment
Gene symbol* Gene name
Unique targets for PRA Unique targets for PRB
APRT Adenine phosphoribosyltransferase ARID5B AT rich interactive domain 5B (MRF1-like)
BNIP1 Bcl2/adenovirus E1B 19-kD protein-interacting protein 
1
ARL1 ADP-ribosylation factor-like 1
CCT6B Chaperonin-containing T-complex polypeptide 1, 
subunit 6B
BRCA2 Breast cancer 2
CLDN4 Claudin 4 C2orf3 Chromosome 2 open reading frame 3
COL4A6 Collagen, type IV, alpha-6 CORT Cortistatin
DNAJB1 DNAJ/HSP40 homolog, subfamily b, member 1 CROT Carnitine O-octanoyltransferase
ECM1 Extracellular matrix protein 1 EIF3I Eukaryotic translation initiation factor 3, subunit I
EXT1 Exostosin 1 ETV1 ETS variant gene 1
EXTL2 Exostosin-like 2 FGF12 Fibroblast growth factor 12
FGF9 Fibroblast growth factor 9 GADD45A Growth arrest- and DNA damage-inducible gene 
GADD45, alpha
FLT1 Fms-related tyrosine kinase 1 GATA2 GATA-binding protein 2
GPLD1 Phospholipase D1, glycosylphosphatidylinositol-specific GTF2F2 General transcription factor IIf, polypeptide 2, 30-kD
IFNAR2 Interferon, alpha, beta, and omega, receptor 2 HES1 Hairy and enhancer of split 1 homolog
ITGA10 Integrin, alpha-10 IHH Indian hedgehog
ITGA2 Integrin, alpha-2 KLK3 Kallikrein-related peptidase 3
ITGB7 Integrin, beta-7 MEF2D Myocyte enhancer factor 2D
KIAA0427 KIAA0427 NCR3 Natural cytotoxicity triggering receptor 3
LAMB1 Laminin, beta-1 NF1 Neurofibromatosis, type I
MAOA Monoamine oxidase A NFIX Nuclear factor I/X (CCAAT-binding transcription factor)
MB Myoglobin NUP98 Nucleoporin, 98-kD
MYST4 Histone acetyltransferase MYST4 POSTN Periostin
NCOA1 Nuclear receptor coactivator 1 PWP1 PWP1 homolog (S. Cerevisiae)
NCOR2 Nuclear receptor corepressor 2 RAD54L Rad54, s. Cerevisiae, homolog-like
NUP155 Nucleoporin, 155-kD RNF126 Ring finger protein 126
PDGFA Platelet-derived growth factor, alpha polypeptide SEMA3F Semaphorin 3F
SLC29A2 Solute carrier family 29 (nucleoside transporter), 
member 2
SNTG1 Syntrophin, gamma-1
SOX4 SRY-box 4 SPATA2 Spermatogenesis-associated protein 2
TGFA Transforming growth factor, alpha SPDEF SAM pointed domain containing ets transcription factor
TIAL1 Tia1 cytotoxic granule-associated rna-binding protein-
like 1
STC1 Stanniocalcin 1
TNC Tenascin C STIM1 Stromal interaction molecule 1
TRIP10 Thyroid hormone receptor interactor 10 TDRKH Tudor and KH domains-containing protein
TRMT11 tRNA methyltransferase 11 homolog (S. Cerevisiae) TLX2 T-cell leukemia, homeobox 2
UBE3C Ubiquitin protein ligase E3C UMOD Uromodulin
UBTF Upstream binding transcription factor 
(RNA polymerase I)
VEGFA Vascular endothelial growth factor A
XCL2 Chemokine, C motif, ligand 2
ZNF549 Zinc finger protein 549
(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).Reproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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Table 4: List of unique target genes for ERα and ERβ in RL95-2 cell line after E2 treatment
Gene symbol* Gene name
Unique targets for ERα Unique targets for ERβ
ANXA2 Annexin A2 ETS2 v-ets avian erythroblastosis virus e26 
oncogene homolog 2
CHRNB2 Cholinergic receptor, neuronal nicotinic, beta polypeptide 2 FOXA2 Forkhead box A2
COL3A1 Collagen, type III, alpha-1 MMP26 Matrix metalloproteinase 26
GSN Gelsolin NINJ1 Nerve injury-induced protein 1
RPS6KB2 Ribosomal protein S6 kinase, 70-kD, 2 SERPIND1 Heparin cofactor II
SECTM1 Secreted and transmembrane 1 SFRS16 Splicing factor, arginine/serine-rich 16
SMARCA2 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily A, member 2
TBX19 T-box 19
SC65 Synaptonemal complex protein SC65 VDAC1 Voltage-dependent anion channel 1
VLDLR Very low density lipoprotein receptor
(*) Official gene symbol by HUGO Gene Nomenclature Committee (HGNC).
Table 5: Genes > 2 fold up- or down-regulated after hormone treatment in HEC1A and/or RL95-2 cell line
Up-regulation > 2 fold ChIP target post E2 treatment ChIP target post P4 treatment
HEC1A Molecular function* E2 P4
MEF2D Other transcription factor; Nucleic acid 
binding
6 h HEC1A ERβ 3 h RL95-2 PRB
RL95-2 E2 P4
CD86 Immunoglobulin receptor family member; 
Membrane-bound signaling molecule; 
Defense/immunity protein
3 h HEC1A ERα NS ND
MEF2D Other transcription factor; Nucleic acid 
binding
3 h HEC1A ERβ 3 h RL95-2 PRB
OTOF Otoferlin 12 h HEC1A ERα and ERβ 3 h HEC1A PRA
PLXNA2 Tyrosine protein kinase receptor;Protein 
kinase
3 h RL95-2 ERβ 3 h RL95-2 PRA
RELB Other transcription factor 3 h HEC1A ERα NS ND
SMARCA2 DNA helicase 3 h RL95-2 ERα 3 h ND
TNC Cell adhesion molecule; Extracellular matrix 
glycoprotein
3 h HEC1A ERβ 3 h RL95-2 PRA
Down-regulation > 2 fold
HEC1A Molecular function* E2 P4
CD86 Immunoglobulin receptor family member; 
Membrane-bound signaling molecule; 
Defense/immunity protein
6 h HEC1A ERα NS ND
FOXA2 Other transcription factor; Nucleic acid 
binding
3 h RL95-2 ERβ 12 h ND
MMP7 Metalloprotease; Other extracellular matrix 12 h HEC1A ERα and ERβ 12 h ND
NCOA1 Transcription factor; Acetyltransferα se 3 h ND 6 h RL95-2 PRA
RELB Other transcription factor 3 h HEC1A ERα 6 h ND
TNC Cell adhesion molecule; Extracellular matrix 
glycoprotein
3 h HEC1A ERβ 6 h RL95-2 PRA
ZNF549 KRAB box transcription factor HEC1A ERα and ERβ 6 h RL95-2 PRA
RL95-2 E2 P4
CD86 Immunoglobulin receptor family member; 
Membrane-bound signaling molecule; 
Defense/immunity protein
12 h HEC1A ERα NS ND
IHH Other signaling molecule; Protease 12 h HEC1A ERα/ERβ 6 h RL95-2 PRB
(*) Molecular functions were obtained from PANTHER. In bold are genes with cell line-specific expression. NS: not significant gene expression, ND: 
not detected. Official gene symbols according to HUGO Gene Nomenclature Committee (HGNC).Reproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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[23,24]. Since NR activity is often tissue specific, we used
primers specifically designed to detect the promoter
regions of 382 genes known to exhibit differential expres-
sion in the human receptive endometrium. Our specific
aim was to investigate whether the steroid hormone
actions in endometrial cell lines HEC1A and RL95-2 sup-
port their use as non-receptive and receptive endometrial
models, respectively.
In non-receptive endometrium, the primary role of E2 is
in tissue regeneration and proliferation. Analysis of the
number of ER target genes identified by ChIP-qPCR after
E2 treatment under our experimental conditions, revealed
E2 mediated time-dependant gene expression in RL95-2 (blue) and HEC1A (red) cell lines compared to non-treated samples Figure 2
E2 mediated time-dependant gene expression in RL95-2 (blue) and HEC1A (red) cell lines compared to non-
treated samples. Expression profiles of CD86, FOXA2, GRIP1, NCOA1, RELB, TBX19, TNC, ZNF549, and MEF2D genes had sig-
nificant difference (p < 0.05, two-tailed, unpaired Student's t-test with 95% confidence of log2-transformed expression ratios 
relative to baseline expression) in mRNA expression ratios (*) between RL95-2 and HEC1A cells after E2 treatment. E2 expo-
sure predominantly induced mRNA level of gene expression in RL95-2 cells but down-regulated in HEC1A cells (except for 
MEF2D gene).
P4 mediated time-dependant gene expression in RL95-2 (blue) and HEC1A (red) cell lines compared to non-treated samples Figure 3
P4 mediated time-dependant gene expression in RL95-2 (blue) and HEC1A (red) cell lines compared to non-
treated samples. Expression profiles of FOXA2, NCOA1, TBX19 and TNC genes had significant difference (p < 0.05, two-
tailed, unpaired Student's t-test with 95% confidence of log2-transformed expression ratios relative to baseline expression) in 
mRNA expression ratios (*) between RL95-2 and HEC1A cells after P4 treatment. P4 mostly induced mRNA level in RL95-2 
cells but down-regulated in HEC1A cells.Reproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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almost 4-fold difference between HEC1A (n = 137) and
RL95-2 (n = 35) cells. This finding supports the idea of
HEC1A as a good model for non-receptive endometrium
being predominantly governed by E2 control. In addition
to unique targets of ERα and ERβ, we identified a subset
of 60 genes in HEC1A cells and 5 genes in RL95-2 cells
that were common for both ERs.
Previous  in vitro studies have demonstrated that both
homodimers ERα/ERα or ERβ/ERβ and heterodimers
ERα/ERβ can be formed when both ER subtypes are
expressed in the same cell [40]. Moreover, it has been
shown that in the absence of ERα, ERβ can either inhibit
ERα-mediated gene transcription or partly replace ERα as
a transcription factor [41]. Thus, the common ERα and
ERβ targets identified in this study could represent genes
either activated by heterodimeric complexes or could
reflect competitive binding of the two separate E2 recep-
tors to the same regulatory element.
In receptive endometrium, the primary role of P4 is the
preparation of the endometrium for embryo implanta-
tion. From our set of 382 genes, 83 were bound by PRs in
RL95-2 cells, which was ten times more than in the
HEC1A cell line (n = 7). Harduf and colleagues have dem-
onstrated that there is a higher PRA/PRB ratio in RL95-2
cells compared to HEC1A cells indicating the possible
important role of PRA during implantation window [22].
Even the both cell lines express E2 and P4 specific recep-
tors (ATCC) the lack of specific antibody against PRA has
made it difficult to compare the exact ratio levels of two
PRs.
To investigate transcriptional changes that occur after NR
binds to its promoter region, we assessed the expression of
20 selected genes. RT-PCR analysis showed that 12 out of
selected 20 IW-specific genes had at least 2-fold up- or
down-regulation in mRNA expression level after hormo-
nal treatment. Five genes were expressed in cell line-spe-
cific manner as the expression of IHH, PLXNA2, OTOF,
and SMARCA2 was only observed in RL95-2 cells, while
MMP7 activity was detected exclusively in HEC1A cells.
We included IHH as a classical example of steroid hor-
mone-dependent gene regulation during IW. Previous in
vivo and in vitro studies revealed that the expression of
IHH  in the murine uterus is solely P4 dependent and
essential for embryo implantation [42-44]. Our results
showed that IHH was the target gene for PRB after P4
treatment in RL95-2 cells. Indeed, RT-PCR analysis con-
firmed IHH expression only in RL95-2 cells. Interestingly,
the mRNA levels of IHH in RL95-2 cells were suppressed
after the use of either E2 or P4 hormones (Table 5), differ-
entially from murine uterus where IHH  expression
depends only on P4 [42-44]. Yet, the recent work has indi-
cated that the stromal not epithelial PR is critical for P4-
mediated induction of IHH  expression in the mouse
uterus [45]. Since the HEC1A and RL95-2 cell lines repre-
sent the epithelial cells of the endometrium, IHH expres-
sion in this endometrial compartment may be regulated
by other hormonal mechanisms from internal tissue lay-
ers. Species difference between the estrous cycle of mice
and the menstrual cycle in women is an additional factor
to account for this discrepancy.
Our gene expression analysis focused mainly on transcrip-
tion factors. Since the development and regeneration of
endometrial tissue is largely governed by E2 and P4, a
transcriptional regulatory feedback system is needed to
mediate these dynamic and complex changes. The major-
ity of E2-regulated genes are thought to be up-regulated
after short (1-8 h) hormonal treatment, while most of the
hormone-responsive genes are down-regulated after
longer (12-48 h) treatment [39]. We examined the
changes in mRNA expression following 3-12 h of hormo-
nal exposure in order to investigate the rapid transcrip-
tional changes caused by steroid hormones. We found
that the increase of mRNA level in selected genes mainly
occurred after short-term (3-6 h) treatment, while the
majority of suppressive effects become visible after 6-12 h
of treatment (Table 5, Figures 2 and 3).
Interestingly, when hormone responsiveness in two
endometrial cell lines was compared, we found that hor-
monal treatments had almost opposite effects on gene
expression. Treatments with E2 or P4 resulted in signifi-
cant up- and down-regulation of genes in RL95-2 and
HEC1A cells, respectively. Genes for the transcription fac-
tors FOXA2, NCOA1, TBX19, and the extracellular matrix
glycoprotein TNC had markedly different and opposite
mRNA expression levels after E2 or P4 treatment in both
of the cell lines investigated. All four genes were either
down-regulated by both hormones in HEC1A or up-regu-
lated in RL95-2 cells (Figures 2 and 3). In addition to
already mentioned genes, E2 had also an inverse effect on
CD86, GRIP1, RELB, and ZNF549 mRNA expression in
the two endometrial cell lines, up-regulated in RL95-2 and
down-regulated in HEC1A cells.
Some of the genes (ADAMDEC1,  ETV1,  FLT1,  HES1,
HOXA1 and KLK3) did not show any evidence of gene
activity in both cell lines in spite of hormonal treatment.
As all genes were selected from previous expression stud-
ies with human endometrium tissue samples the revealed
effect could be cell line specific. In addition, we have to
take into account that NR binding alone is not always suf-
ficient to induce gene expression changes. The various
combinations of transcription co-activators or -repressors
are also required for proper gene activity, depending on
the specific cell and tissue background [46-48]. In study-Reproductive Biology and Endocrinology 2009, 7:150 http://www.rbej.com/content/7/1/150
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ing steroid hormone signalling, the non-genomic actions
of steroid hormones in cross-talk between the growth fac-
tor receptors and cytoplasmic response must also be con-
sidered along with the direct transcriptional effects
mediated by NRs [49,50].
In present study we gained new information about the
specific action of E2 and P4 during different stages of
human endometrial development using a combination of
ChIP-qPCR and RT-PCR. HEC1A and RL95-2 cell lines
showed different sets of ER and PR target genes in
response to hormonal stimuli as more target genes were
detected for ERs in HEC1A cells than for PRs in RL95-2
cells. We also observed that hormone treatment had dif-
ferent impacts on gene expression levels in the two cell
lines. The ChIP and RT-PCR results show that E2 and P4
actions in the human endometrium are more complex
than the classic steroid hormone effects mediated through
NRs.
Conclusions
The presented data demonstrates that the endometrial cell
lines HEC1A and RL95-2 are suitable in vitro models for
evaluating the effects of steroid hormones in non-recep-
tive and receptive endometrium, respectively. This study
deepens our understanding on the hormone responsive
gene regulation during the cyclic changes in the human
endometrium. However, further studies are needed to elu-
cidate the complex mechanism by which endometrium
acquires its receptivity.
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